Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1321 AL 1335

Medical conditions of nursing home admissions

Van Rensbergen G, Nawrot T.

BMC Geriatr. 2010 Jul 14;10:46. doi: 10.1186/1471-2318-10-46.

Wolff-Parkinson-White syndrome in infants

Hermosura T, Bradshaw WT.

Neonatal Netw. 2010 Jul-Aug;29(4):215-23. doi: 10.1891/0730-0832.29.4.215.

Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors

Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP.

Neuropsychopharmacology. 2010 Oct;35(11):2155-64. doi: 10.1038/npp.2010.84. Epub 2010 Jul 14.

Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders

White CM, Ji S, Cai H, Maudsley S, Martin B.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):661-6. doi: 10.2174/187152710793361595.

Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics

Albizu L, Moreno JL, González-Maeso J, Sealfon SC.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):636-50. doi: 10.2174/187152710793361586.

Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D₁-D₃ receptor heteromer

Ferré S, Lluis C, Lanciego JL, Franco R.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):596-600. doi: 10.2174/187152710793361603.

Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration

Cadet JL, Jayanthi S, McCoy MT, Beauvais G, Cai NS.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):526-38. doi: 10.2174/187152710793361496.

Statins and neuroprotection: a prescription to move the field forward

Wood WG, Eckert GP, Igbavboa U, Müller WE.

Ann N Y Acad Sci. 2010 Jun;1199:69-76. doi: 10.1111/j.1749-6632.2009.05359.x.

Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism

Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin L, Price AB, Ibrahim MA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, Peterson DW.

Helicobacter. 2010 Aug;15(4):279-94. doi: 10.1111/j.1523-5378.2010.00768.x.

Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease

Kulaksizoglu H, Parman Y.

Parkinsonism Relat Disord. 2010 Sep;16(8):531-4. doi: 10.1016/j.parkreldis.2010.06.006. Epub 2010 Jul 15.

Microglia: activation in acute and chronic inflammatory states and in response to cardiovascular dysfunction

Badoer E.

Int J Biochem Cell Biol. 2010 Oct;42(10):1580-5. doi: 10.1016/j.biocel.2010.07.005. Epub 2010 Jul 16.

Treadmill exercise test in Wolff-Parkinson-White syndrome

Kurisu S.

Clin Cardiol. 2010 Jul;33(7):E47. doi: 10.1002/clc.20682.

Non-motor symptoms of Parkinson's disease: diagnosis and management

Salawu FK, Danburam A, Olokoba AB.

Niger J Med. 2010 Apr-Jun;19(2):126-31. doi: 10.4314/njm.v19i2.56496.

Dopamine D2 receptors as treatment targets in schizophrenia

Seeman P.

Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73.

Voice and fluency changes as a function of speech task and deep brain stimulation

Van Lancker Sidtis D, Rogers T, Godier V, Tagliati M, Sidtis JJ.

J Speech Lang Hear Res. 2010 Oct;53(5):1167-77. doi: 10.1044/1092-4388(2010/09-0154). Epub 2010 Jul 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias